Status:

COMPLETED

Effect of Combined IV Bolus Amino Acid Supplementation and Mobilisation on Skeletal Muscle During the First 10 Days in the ICU: A RCT

Lead Sponsor:

University of Stellenbosch

Collaborating Sponsors:

Fresenius Kabi

University of the Western Cape

Conditions:

Critical Illness

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

A single-centre, two-arm, parallel randomised controlled trial (RCT) to compare the combined effect of early intravenous bolus amino acid supplementation and mobilisation versus standard of care on ch...

Detailed Description

Critical illness survivors often suffer from severe muscle mass depletion and a profound long-term functional impairment. Hence effective strategies, or a combination of strategies, are needed to redu...

Eligibility Criteria

Inclusion

  • Adult patient (≥18 years) admitted to medical/surgical ICU of Tygerberg Academic Hospital (TBH)
  • Expected length of mechanical- or non-invasive ventilation \> 48 hours
  • Receiving enteral (EN) and/or parenteral nutrition (PN) as per standard care and for a minimum of 5 days
  • Expected ICU length of stay of 7 days

Exclusion

  • Spinal cord lesion or intracranial process associated with muscle weakness
  • Acute/chronic degenerative neuromuscular condition
  • Fulminant hepatic failure/severe chronic liver disease (MELD score ≥20) or renal failure (based on KDIGO) not on Renal Replacement Therapy
  • Untreated thrombosis, or thrombosis where therapeutic levels of anticoagulants have not been reached at the time of inclusion
  • Any condition deemed inappropriate by the overseeing doctor- such as precautions or contraindications related to the movement as a result of trauma and/or surgery to the spine, pelvis or lower limbs, or haemodynamic instability.
  • Other: imminent death or withdrawal of treatment, pregnancy, lower limb amputation/s or fractures, readmission after previous randomisation, long-term corticosteroid therapy, morbidly obese (BMI ≥ 40kg/m2)

Key Trial Info

Start Date :

May 24 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2022

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT04099108

Start Date

May 24 2021

End Date

December 31 2022

Last Update

December 3 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tygerberg Hospital

Cape Town, Western Cape, South Africa, 7505